Walleye Capital LLC Sells 47,163 Shares of Keros Therapeutics, Inc. $KROS

Key Points

• Walleye Capital LLC reduced its holdings in Keros Therapeutics by 23.9%, selling 47,163 shares and now owning approximately 150,503 shares valued at $1.53 million as of the latest SEC filing.
• Several hedge funds have shown varied interest in Keros Therapeutics, with GAMMA Investing LLC increasing its stake by an astonishing 7,690.3% during the 1st quarter.
• Analysts have lowered their price targets for Keros Therapeutics, with Scotiabank reducing their target from $41 to $26, indicating a cautious outlook amidst varied ratings from seven analysts.

Walleye Capital LLC cut its position in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 23.9% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 150,503 shares of the company's stock after selling 47,163 shares during the quarter. Walleye Capital LLC owned approximately 0.37% of Keros Therapeutics worth $1,534,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of the company. FNY Investment Advisers LLC bought a new position in Keros Therapeutics during the 1st quarter worth approximately $25,000. CWM LLC grew its position in Keros Therapeutics by 10,157.7% during the 1st quarter. CWM LLC now owns 2,667 shares of the company's stock worth $27,000 after acquiring an additional 2,641 shares during the last quarter. Entropy Technologies LP bought a new position in Keros Therapeutics during the 1st quarter worth approximately $121,000. AlphaQuest LLC grew its position in Keros Therapeutics by 268.0% during the 1st quarter. AlphaQuest LLC now owns 13,234 shares of the company's stock worth $135,000 after acquiring an additional 9,638 shares during the last quarter. Finally, ProShare Advisors LLC grew its position in Keros Therapeutics by 35.5% during the 4th quarter. ProShare Advisors LLC now owns 10,549 shares of the company's stock worth $167,000 after acquiring an additional 2,764 shares during the last quarter. 71.56% of the stock is currently owned by institutional investors.

Keros Therapeutics Stock Performance

Shares of Keros Therapeutics stock traded up $0.51 during trading hours on Tuesday, hitting $15.72. The company's stock had a trading volume of 475,978 shares, compared to its average volume of 959,202. The business has a 50 day moving average price of $14.22 and a two-hundred day moving average price of $13.21. Keros Therapeutics, Inc. has a 12-month low of $9.12 and a 12-month high of $72.37. The company has a market cap of $638.55 million, a PE ratio of 50.71, a PEG ratio of 1.96 and a beta of 1.06.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($0.76) EPS for the quarter, beating the consensus estimate of ($1.14) by $0.38. The business had revenue of $0.02 million for the quarter, compared to the consensus estimate of $3.83 million. Keros Therapeutics had a return on equity of 2.96% and a net margin of 8.06%.The business's revenue was up 49002.7% on a year-over-year basis. During the same period in the previous year, the business earned ($1.25) earnings per share. As a group, research analysts anticipate that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current year.

Analyst Ratings Changes

KROS has been the topic of several recent research reports. Bank of America lowered Keros Therapeutics from a "buy" rating to a "neutral" rating and reduced their price target for the stock from $32.00 to $18.00 in a research report on Tuesday, June 10th. HC Wainwright cut their price objective on Keros Therapeutics from $25.00 to $20.00 and set a "buy" rating on the stock in a research report on Friday, August 8th. Wedbush reiterated a "neutral" rating and issued a $15.00 price objective on shares of Keros Therapeutics in a research report on Friday, May 30th. Finally, Scotiabank lowered their target price on Keros Therapeutics from $41.00 to $26.00 and set a "sector outperform" rating for the company in a research note on Monday, May 12th. Seven research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $30.00.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.